Patent ID: 8349581

Claim:
A method of determining if a patient with chest pain is at risk of experiencing a major cardiac event within 1 to 6 months of presenting with chest pain, comprising: a) determining levels of one or more select myeloperoxidase-generated oxidation products in a bodily sample from the patient, wherein said bodily sample is urine, serum, plasma, or a combination thereof, wherein each of said select myeloperoxidase (MPO)-generated oxidation product is an MPO-generated lipid peroxidation product selected from hydroxy-eicosatetraenoic acids (HETEs); hydroxy-octadecadienoic acids (HODEs), F2Isoprostanes; the glutaric and nonanedioic monoesters of 2-lysoPC (G-PC and ND-PC, respectively); the 9-hydroxy-10-dodecenedioic acid and 5-hydroxy-8-oxo-6-octenedioic acid esters of 2-lysoPC (HDdiA-PC and HOdiA-PC, respectively); the 9-hydroxy-12-oxo-10-dodecenoic acid and 5-hydroxy-8-oxo-6-octenoic acid esters of 2-lysoPC (HODA-PC and HOOA-PC, respectively); the 9-keto-12-oxo-10-dodecenoic acid and 5-keto-8-oxo-6-octenoic acid esters of 2-lysoPC (KODA-PC and KOOA-PC, respectively); the 9-keto-10-dodecendioic acid and 5-keto-6-octendioic acid esters of 2-lysoPC (KDdiA-PC and KOdiA-PC, respectively); the 5-oxovaleric acid and 9-oxononanoic acid esters of 2-lysoPC (OV-PC and ON-PC, respectively) or any combination thereof; and b) comparing the levels of each of said select myeloperoxidase-generated oxidation product in the bodily sample from the human patient with a control value; wherein a patient whose levels of said select MPO-generated oxidation product are elevated as compared to the control value is at risk of experiencing a major cardiac event within 6 months after presenting with chest pain.